These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38968798)

  • 1. The secoiridoid glycoside Gentiopicroside is a USP22 inhibitor with potent antitumor immunotherapeutic activity.
    Lu W; Chu P; Tang A; Si L; Fang D
    Biomed Pharmacother; 2024 Aug; 177():116974. PubMed ID: 38968798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms.
    Guo J; Zhao J; Fu W; Xu Q; Huang D
    Front Immunol; 2022; 13():918314. PubMed ID: 35935969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
    Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
    Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity.
    Huang X; Zhang Q; Lou Y; Wang J; Zhao X; Wang L; Zhang X; Li S; Zhao Y; Chen Q; Liang T; Bai X
    Cancer Immunol Res; 2019 Oct; 7(10):1580-1590. PubMed ID: 31399419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 Inhibition Enhances PD-L1 Protein Stability Through USP22-Mediated Deubiquitination in Colorectal Cancer.
    Huang J; Yin Q; Wang Y; Zhou X; Guo Y; Tang Y; Cheng R; Yu X; Zhang J; Huang C; Huang Z; Zhang J; Guo Z; Huo X; Sun Y; Li Y; Wang H; Yang J; Xue L
    Adv Sci (Weinh); 2024 Jun; 11(23):e2308045. PubMed ID: 38520088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR screen in regulatory T cells reveals modulators of Foxp3.
    Cortez JT; Montauti E; Shifrut E; Gatchalian J; Zhang Y; Shaked O; Xu Y; Roth TL; Simeonov DR; Zhang Y; Chen S; Li Z; Woo JM; Ho J; Vogel IA; Prator GY; Zhang B; Lee Y; Sun Z; Ifergan I; Van Gool F; Hargreaves DC; Bluestone JA; Marson A; Fang D
    Nature; 2020 Jun; 582(7812):416-420. PubMed ID: 32499641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
    Chen T; Dong Y; Wu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of selective and potent USP22 inhibitors via structure-based virtual screening and bioassays exerting anti-tumor activity.
    Zhang Y; Song J; Zhou Y; Jia H; Zhou T; Sun Y; Gao Q; Zhao Y; Pan Y; Sun Z; Chu P
    Bioorg Chem; 2023 Dec; 141():106842. PubMed ID: 37769523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered Hybrid Treg-Targeted Nanosomes Restrain Lung Immunosuppression by Inducing Intratumoral CD8
    Domvri K; Petanidis S; Zarogoulidis P; Anestakis D; Charalampidis C; Tsavlis D; Huang H; Freitag L; Hohenforst-Schmidt W; Matthaios D; Katopodi T; Porpodis K
    Int J Nanomedicine; 2022; 17():4449-4468. PubMed ID: 36172007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.
    Alderson KL; Zhou Q; Berner V; Wilkins DE; Weiss JM; Blazar BR; Welniak LA; Wiltrout RH; Redelman D; Murphy WJ
    J Immunol; 2008 Mar; 180(5):2981-8. PubMed ID: 18292520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
    Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S
    Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
    Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
    Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. USP22 controls iNKT immunity through MED1 suppression of histone H2A monoubiquitination.
    Zhang Y; Wang Y; Gao B; Sun Y; Cao L; Genardi SM; Wang CR; Li H; Sun Z; Yang Y; Fang D
    J Exp Med; 2020 May; 217(5):. PubMed ID: 32069354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
    Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
    Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
    Zhang K; Yang L; Wang J; Sun T; Guo Y; Nelson R; Tong TR; Pangeni R; Salgia R; Raz DJ
    Cell Commun Signal; 2019 Dec; 17(1):167. PubMed ID: 31842906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
    Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
    Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.